HRs for PFS and survival according to baseline characteristics on univariable analysis
| Baseline characteristics . | PFS HR (95% CI) . | P . | OS HR (95% CI) . | P . |
|---|---|---|---|---|
| Age ≥65, n = 72 | 1.59 (1.17-2.17) | .003 | 2.66 (1.90-3.72) | <.001 |
| Male gender, n = 211 | 1.24 (0.91-1.69) | .179 | 1.29 (0.89-1.88) | .177 |
| B2M ≥4.0 (mg/L), n = 128 | 1.97 (1.49-2.61) | <.001 | 2.51 (1.80-3.49) | <.001 |
| Unmutated IGHV, n = 126 | 3.62 (2.50-5.24) | <.001 | 2.62 (1.71-4.01) | <.001 |
| ECOG PS >0, n = 181 | 1.25 (0.94-1.67) | .123 | 1.32 (0.97-1.78) | .076 |
| Rai stage III-IV, n = 107 | 1.27 (0.95-1.69) | .101 | 1.34 (0.96-1.87) | .081 |
| WCC >200 × 109/L, n = 27 | 2.51 (1.63-3.86) | <.001 | 1.90 (1.16-3.11) | .011 |
| LDH > normal, n = 108 | 1.53 (1.15-2.03) | .003 | 1.64 (1.18-2.27) | .003 |
| ZAP70 IHC pos, n = 126 | 2.44 (1.68-3.54) | <.001 | 1.84 (1.22-2.79) | .004 |
| Karyotype: del(17p), n = 5 | 4.18 (1.70-10.24) | .002 | 4.52 (1.66-12.37) | .003 |
| Baseline characteristics . | PFS HR (95% CI) . | P . | OS HR (95% CI) . | P . |
|---|---|---|---|---|
| Age ≥65, n = 72 | 1.59 (1.17-2.17) | .003 | 2.66 (1.90-3.72) | <.001 |
| Male gender, n = 211 | 1.24 (0.91-1.69) | .179 | 1.29 (0.89-1.88) | .177 |
| B2M ≥4.0 (mg/L), n = 128 | 1.97 (1.49-2.61) | <.001 | 2.51 (1.80-3.49) | <.001 |
| Unmutated IGHV, n = 126 | 3.62 (2.50-5.24) | <.001 | 2.62 (1.71-4.01) | <.001 |
| ECOG PS >0, n = 181 | 1.25 (0.94-1.67) | .123 | 1.32 (0.97-1.78) | .076 |
| Rai stage III-IV, n = 107 | 1.27 (0.95-1.69) | .101 | 1.34 (0.96-1.87) | .081 |
| WCC >200 × 109/L, n = 27 | 2.51 (1.63-3.86) | <.001 | 1.90 (1.16-3.11) | .011 |
| LDH > normal, n = 108 | 1.53 (1.15-2.03) | .003 | 1.64 (1.18-2.27) | .003 |
| ZAP70 IHC pos, n = 126 | 2.44 (1.68-3.54) | <.001 | 1.84 (1.22-2.79) | .004 |
| Karyotype: del(17p), n = 5 | 4.18 (1.70-10.24) | .002 | 4.52 (1.66-12.37) | .003 |